Dr. Jean-Yves GOUJON
PhD defense in 2000: « New synthetic methods of substituted benzopyrans» (Dr. Bernard Kirschleger – Nantes University (FR) – LSO – UMR6513))
Post-doctoral experience 2001-2002: « Synthesis of antitumoral agent : azinomycins » (Dr. Mike Shipman – Exeter University (GB))
Post-doctoral experience 2002-2003: « Iminosugar synthesis » (Dr. Olivier Martin – Orléans University (FR) – ICOA – UMR6005)
Post-doctoral experience 2003-2004: « Synthesis on ionic liquid » (Dr. Jean-Pierre Bazureau – Rennes1 University (FR) UMR6510)
Project leader, 2004-2011: Atlanchim Pharma
Project leader, 2011-2024: Atlanthera
Publications
“Enantioselective Synthesis of Cordiachromene” Eur. J. Org. Chem. 2000, 18, 3223-3228.
“Synthesis of various 2H-1-benzopyran compounds and their kinetic resolution by asymmetric hydrolysis of their racemic acetates mediated by lipases” Tetrahedron: Asymmetry 2000, 11, 2409-2420.
“A useful enantioselective synthesis of chromanmethanol” J. Chem. Soc., Perkin Trans 1 2002, 496-499.
“A New and Efficient Synthesis of Substituted 2-Hydroxymethyl-2-methyl-2H-chromenes” Synlett 2002, 322-324.
“Expeditious preparation of various Δ–6a,10a cis and trans 2-substituted tetrahydrocannabinoids” J. Chem. Soc., Perkin Trans 1 2002, 1564-1567.
“Concise route to α-acylamino-β-keto amides : application to the synthesis of a simplified azinomycin A analogue” Tetrahedron. Lett. 2002, 43, 9573-9576.
“Ring-opening reaction of iminosugar-derived aziridines: Application to the general synthesis of a-1-C-substituted derivatives of fagomine” Tetrahedron: Asymmetry” 2003, 14, 1969-1972.
“A new approach to 2,2-disubstituted chromenes and tetrahydoquinolines throught intramolecular cyclization of chiral 3,4-epoxyalcohols” Tetrahedron 2004, 60, 4037-4049.
“General synthesis and biological evaluation of α-1-C-substituted derivatives of fagomine” Bioorg. Med. Chem. 2005, 13, 6, 2313-2324.
“Liquid-Phase Synthesis of Polyhydroquinoline Using Task-Specific Ionic Liquid Technology” J. Comb. Chem. 2006, 8, 829-833.
“Bifunctional hydroxy-biphosphonic acid derivatives” WO2012130911.
“Synthesis of hydrosoluble hydroxybisphosphonic derivatives of doxorubicin for use in treatment of bone cancer” WO2016079327.
“Synthesis of a high specific activity methyl sulfone tritium isotopologue of fevipiprant (NVP-QAW039) ” J. Label. Compd Radiopharm. 2015, 58, 188-195.
“12b80 -Hydroxybisphosphonate Linked Doxorubicin: Bone Targeted Strategy for Treatment of Osteosarcoma” Bioconjugate Chemistry 2019, 30, 6, 1665-1676.
“Hydroxybisphosphonic derivatives of Meloxicam for the treatment of inflammatory joint diseases” WO2022229576.
